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Abstract
Background: The efficacy of the H1N1 influenza vaccine relies on the induction of both humoral and cellular responses.
This study evaluated the humoral and cellular responses to a monovalent non-adjuvanted pandemic influenza A/H1N1
vaccine in occupationally exposed subjects who were previously vaccinated with a seasonal vaccine.
Methods: Sixty healthy workers from a respiratory disease hospital were recruited. Sera and peripheral blood
mononuclear cells (PBMCs) were obtained prior to and 1 month after vaccination with a non-adjuvanted monovalent
2009 H1N1 vaccine (Influenza A (H1N1) 2009 Monovalent Vaccine Panenza, Sanofi Pasteur). Antibody titers against the
pandemic A/H1N1 influenza virus were measured via hemagglutination inhibition (HI) and microneutralization assays.
Antibodies against the seasonal HA1 were assessed by ELISA. The frequency of IFN-γ-producing cells as well as CD4+ and
CD8+ T cell proliferation specific to the pandemic virus A/H1N peptides, seasonal H1N1 peptides and seasonal
H3N2 peptides were assessed using ELISPOT and flow cytometry.
Results: At baseline, 6.7% of the subjects had seroprotective antibody titers. The seroconversion rate was 48.3%,
and the seroprotection rate was 66.7%. The geometric mean titers (GMTs) were significantly increased (from 6.8 to
64.9, p < 0.05). Forty-nine percent of the subjects had basal levels of specific IFN-γ-producing T cells to the pandemic
A/H1N1 peptides that were unchanged post-vaccination. CD4+ T cell proliferation in response to specific pandemic
A/H1N1 virus peptides was also unchanged; in contrast, the antigen-specific proliferation of CD8+ T cells significantly
increased post-vaccination.
Conclusion: Our results indicate that a cellular immune response that is cross-reactive to pandemic influenza antigens
may be present in populations exposed to the circulating seasonal influenza virus prior to pandemic or seasonal
vaccination. Additionally, we found that the pandemic vaccine induced a significant increase in CD8+ T cell proliferation.
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Background
In the spring of 2009, the most recent pandemic of the
A/H1N1 influenza virus originated in Mexico, eventually
becoming a major worldwide public health threat [1].
With the goal of protecting high-risk populations, differ-
ent vaccine formulations were produced that yielded high
seroprotection and seroconversion rates in healthy sub-
jects; high antibody titers were observed beginning on day
10 after vaccination and were sustained up to day 45
[2-4]. Mexican health authorities began by administering
the vaccine to high-risk groups including hospital em-
ployees who had previously received the seasonal influ-
enza vaccine. The employees of the National Institute
of Respiratory Diseases in Mexico City were vaccinated
with the non-adjuvanted monovalent pandemic influenza
A/H1N1 vaccine manufactured by Sanofi Pasteur, a vac-
cine that was based on the virus strain recommended by
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the World Health Organization for the development of
the influenza A (H1N1) vaccine [5]. The antibody re-
sponse to the Sanofi Pasteur vaccine has been reported
to range from good to moderate in different high-risk
populations [6-9]. Nevertheless, our knowledge regard-
ing the induction of cellular responses to this vaccine
remains limited.
In addition to a humoral response, this vaccine is
expected to promote the development of cell-mediated
immune responses [10]. Cellular immune responses, me-
diated by CD4+ and CD8+ T cells, contribute to essential
surveillance against the influenza virus via cytokine modu-
lation and the cross-reactivity that exists among virus-
specific cytotoxic T cells [11]. Moreover, the use of the
IFN-γ ELISPOT assay has successfully demonstrated
the existence of circulating memory CD4+ and CD8+
T cells that are cross-reactive with the pandemic virus
in healthy donors irrespective of any prior seasonal vac-
cination or exposure to this novel virus [11-14].
The present study was initiated after the first pan-
demic wave in Mexico occurred and was conducted as a
longitudinal study in employees of the National Institute
of Respiratory Diseases in Mexico City. This study was
conducted to evaluate the immunogenicity of a single-
dose administration of a monovalent non-adjuvanted
pandemic influenza A/H1N1 vaccine in individuals who
had previously received the trivalent 2008 or 2009 seasonal
influenza vaccine. We evaluated the level of protection
of the pandemic A/H1N1 vaccine according to specific




We recruited 60 healthy subjects at random who intended
to receive the pandemic influenza vaccine through a pub-
lic institutional vaccine program for employees of the
National Institute of Respiratory Diseases in Mexico City;
of these subjects, 45 (75%) had received the 2009 seasonal
vaccine (Fluzone 2009–2010 trivalent A/Brisbane/59/2007
(H1N1)-like, A Brisbane/10/2007 (H3N2)-like and
B/Brisbane/60/2008-like strains) in October 2009, and 5
subjects (8.3%) had received the 2008 trivalent seasonal
vaccine (Fluzone 2008–2009 A/Solomon Islands/3/2006
(H1N1), A Wisconsin /67/2005 (H3N2) B Malaysia/2506/
2004). The authors did not vaccinate the cohort, and this
was not a trial study. The subjects were recruited from
December 2009 to January 2010. All volunteers received
a single dose of the non-adjuvanted monovalent 2009
H1N1 vaccine (Influenza A (H1N1) 2009 Monovalent
Vaccine Panenza, Sanofi Pasteur). The volunteers con-
sented to undergo venipuncture prior to and 1month
after pandemic influenza A/H1N1 vaccination. We ob-
tained paired samples for the isolation of serum and
peripheral blood mononuclear cells (PBMCs). All par-
ticipants signed an informed consent form, and the local
Institutional Review Boards approved this protocol.
Peptides
We used custom-designed peptides that were synthe-
sized by Enzo Life Sciences (Ann Arbor, MI, U.S.A.) and
designed on the basis of their conservation level for viral
strain discrimination. The regions of the hemagglutinin
(HA) sequences of the 2009 pandemic H1N1 and sea-
sonal H1N1 and H3N2 viruses that were unique to these
viruses were selected and analyzed. All HA sequences
from the National Center for Biotechnology Information
(NCBI) Influenza Virus Sequence Database available in
2009 were downloaded and aligned using the ClustalW
(FASTA) tool, which is free and available on the NCBI
website [15]. Protein consensus sequences were gener-
ated and independently analyzed for each virus subtype;
the scores for conservation or synonymous substitutions
were identified for each position. The selected sequences
contained putative MHC class I and class II epitopes with
low and high affinity for HLA alleles that are frequently
found in the Mexican population [16]. These sequences
were validated with the SYFPEITHI epitope prediction
tool and the ProPred MHC class II binding prediction
server [17] (see Additional file 1: Table S1).
Lyophilized peptides were dissolved in RPMI 1640
medium (Lonza, Walkersville, MD) containing 20% di-
methyl sulfoxide (DMSO, Sigma-Aldrich, St Louis, MO),
frozen at −70°C and diluted at a ratio of 1:1,000 with
RPMI 1640 medium containing 2 mM L-glutamine
(Sigma-Aldrich) and 50 μg/ml gentamicin sulfate (Lonza),
herein termed “supplemented medium”.
Sera and cells
After blood samples were collected from the volunteers,
serum was obtained via centrifugation and stored at −70°C
until use. PBMCs were isolated from heparinized blood
diluted at a 1:2 ratio with supplemented medium and
separated via centrifugation using a lymphocyte separ-
ation solution (Lonza). The PBMCs were washed, counted
and cryopreserved in fetal bovine serum (FBS, Hyclone,
Logan, UT) containing 10% DMSO at −70°C until use.
For the cellular response analysis, cryopreserved PBMCs
were thawed and re-suspended in supplemented medium
(viability ≥ 90%).
Antibody detection
Antibodies specific to the influenza pandemic virus were
identified using hemagglutination inhibition and micro-
neutralization assays. Briefly, serial 2-fold dilutions of
the previously inactivated serum were assayed for their
ability to inhibit the agglutination of chicken red blood
cells in the presence of the A/H1N1/California/07/2009
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influenza virus. Serum dilutions (starting at 1:5) were
tested in duplicate, and titers are expressed as the recip-
rocal of the highest dilution that produced complete
hemagglutination or 50% neutralization, respectively [18].
The antibody response was assessed using the criteria of
the European Agency for the Evaluation of Medicinal
Products (EMA) for 18- to 60-year-old subjects and was
based on the geometric mean titers (GMTs), seropro-
tection rate (percentage of subjects with HI antibody
titers ≥ 1:40) and seroconversion rate (percentages of sub-
jects with either pre-vaccination HI antibody titers ≤ 1:10
and post-vaccination titers ≥ 1:40 or pre-vaccination HI
antibody titers ≥ 10 and at least a 4-fold increase in post-
vaccination HI antibody titers). In accordance with the
EMA, these criteria include a seroprotection rate ≥ 70%, a
seroconversion rate ≥ 40% and a GMT fold increase of
2.5; these 3 parameters must be fulfilled for acceptable
pandemic influenza vaccines [19]. We also determined
the levels of anti-H1 hemagglutinin (HA1) IgG antibodies
in the serum using a commercial ELISA kit (Cusabio,
Biotech Co., Newark, DE) according to the manufacturer’s
instructions. The results are expressed as the OD at
450 nm. A sample was considered seropositive when its
OD was ≥ 0.4.
Human IFN-γ ELISPOT assay
The frequency of antigen-specific IFN-γ-producing T cells
upon stimulation with HA peptides was assessed using
ELISPOT, as previously described [20,21]. In brief, multi-
screen 96-well filter plates (Millipore Corporation, Billerica,
MA) were incubated overnight at 4°C with anti-human
IFN-γ antibody (Endogen, Woburn, MA). The plates were
blocked with 1% bovine serum albumin (BSA, Calbiochem,
La Jolla, CA), and 2.5 × 105 PBMCs/well were seeded and
incubated for 48 h with individual peptides (10 μg/ml), a
mix of peptides (2 μg/ml each) or the recombinant HA
A/H1N1/California/06/2009 (Immune Tech., Foster City,
CA). Phytohemagglutinin (10 μg/ml) (PHA, Sigma-Aldrich)
was included as the positive control, and the medium alone
culture served as the negative control (background). The
cells were removed, and biotinylated-anti-human IFN-γ
antibody (Endogen) was added and allowed to incubate
for 2 h. Peroxidase-streptavidin (Dako, Glostrup, Denmark)
was added, and the spots were visualized after the addition
of 1% 3-amino-9-ethylcarbazole (AEC, Pierce, Rockford, IL).
Spot-forming cells (SFCs) were counted using an Immuno-
Spot reader (Cellular Technology Ltd, Cleveland, OH). The
frequency of IFN-γ-producing cells was calculated by
averaging the number of spots in duplicate wells after
background subtraction. The results are expressed as
SFCs/106 PBMCs. Subjects whose IFN-γ response exceeded
the background response by at least 6 spots were considered
specific responders.
T cell proliferation assay
To evaluate the proliferative response after pandemic
A/H1N1 vaccination, we examined the percentage of pro-
liferating peripheral CD4+ and CD8+ T cells following
stimulation with H1N1 peptides. This analysis utilized
the carboxyfluorescein diacetate succinimidyl ester (CFSE)
dilution model, in which the CFSE signal is divided be-
tween daughter cells and shows peaks with diminishing
fluorescence at an approximate ratio of 0.5 per cell div-
ision. We analyzed each round of cell division of CD8+
and CD4+ T cells in response to the H1N1 peptides. Briefly,
the PBMCs were labeled with CFSE (Sigma-Aldrich),
placed in a PBS/2% BSA solution for 15 min at 37°C and
washed twice with PBS. The cells were then seeded in
ultralow attachment 24-well plates (Costar-Corning
Incorporated, Corning, NY) at 1 × 106 PBMCs/well and
stimulated with 10 μg/ml of the individual influenza
peptides. PHA (10 μg/ml) was included as a positive
control, and medium alone served as the negative con-
trol. The plates were incubated at 37°C with 5% CO2 for
7 days. The cells were subsequently stained with monoclo-
nal anti-human antibodies including CD3-PE-Texas Red
(Invitrogen Gibco, Grand Island, NY), CD8-PE-Cy7
and CD4-APC-Cy7 (BioLegend, San Diego, CA). Then,
1 × 104 events were recorded for each condition using a
FACSCanto II flow cytometer (Becton Dickinson), and
the data were analyzed with the FlowJo proliferation
platform (FlowJo 9.4.10, Tree Star, Inc., Ashland, OR).
The peptide-specific proliferation of CD3+/CD8+/CFSE+
or CD3+/CD4+/CFSE+ cells was calculated by subtracting
the number of proliferating cells in the negative con-
trol. Individuals with a positive proliferative response
were defined as subjects with ≥ 2% proliferating cells
(based on the summed responses to peptides 1 and 2
and the total proliferation).
Statistical methods
Differences in antibody production and IFN-γ responses
elicited by the specific peptides and the proliferation
of CD8+ and CD4+ T cells pre- and post-vaccination were
analyzed using the Wilcoxon signed rank test. Differences
in proliferation between the influenza serotypes were
analyzed using the Kruskal-Wallis test, followed by Dunn's
multiple comparison test. Associations of age, gender and
area of work at the hospital with pre- and post-vaccination
antibody titers were assessed using the chi-square test. We
used the Spearman rank correlation test to assess whether
age, gender or work activity at the hospital was associated
with neutralizing antibody titers or T cell responses. To
our knowledge there are no published data describing
the mean difference in CD8+ T cells between pre- and
post-H1N1 pandemic influenza vaccination. We therefore
estimated our sample size based on an analysis of the first
10 pairs of subjects among whom we observed that the
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difference in response was not normally distributed
(median 3.8, IQR (1.44-7.09). We calculated the sample
size needed for a two-sample t-test (alpha = 0.05 and
beta = 0.8) using a mean of 3.8 and standard deviation
of 4, arriving at 33 pairs, and then adjusted the sample
size based on the asymptotic relative efficiency of the
Mann–Whitney U relative to the t-test (worst case sce-
nario, dividing 33 by 0.864), arriving at 38 pairs [22].
The statistical analyses were performed using SPSS
15.0 for Windows (SPSS, Chicago, IL) and Prism 5.0
(GraphPad, La Jolla, CA). Two-tailed p-values < 0.05 were
considered statistically significant.
Results and discussion
Description of the cohort
Sixty subjects were enrolled in the present study; all of
the subjects were employees of the National Institute of
Respiratory Diseases in Mexico City, which is a reference
center for pandemic influenza patients. All subjects were
actively working during the pandemic wave of the influ-
enza A/H1N1 virus (2009), which originated in Mexico.
Forty-five (75%) of the subjects were previously vaccinated
with the trivalent influenza seasonal vaccine in October
2009, and 5 (8.3%) of the subjects were vaccinated with
the 2008 trivalent influenza seasonal vaccine before
October 2009. The occupations of the participants in-
cluded research, clinical practice and administrative func-
tions. None of the subjects had been diagnosed as having
influenza prior to or after A/H1N1 vaccination. Table 1
summarizes the characteristics of the study group. The
variables of age, gender, prior seasonal vaccination status
and area of work were not associated or correlated with
the humoral or cellular responses described below.
Antibody responses to the pandemic A/H1N1 vaccine
The immunogenicity of the vaccine against influenza
A/H1N1 was assessed according to the antibody titer after
vaccination. Here, we determined the serum levels of anti-
bodies against the pandemic virus using a hemagglutination
inhibition assay, which is a standard assay used in the
process of licensing influenza vaccines. Prior to 2009
A/H1N1 virus vaccination, the baseline seroprotective rate
of the subjects was 6.7%, and the GMT was 6.8 (Figure 1a
and Table 2). The proportion of subjects with titers ≥ 1:40
in the hemagglutination inhibition assay at baseline was
lower than expected for such an exposed population con-
sidering the previous vaccination with the 2008 and 2009
seasonal influenza vaccines in 83% of the subjects; these
titers were also lower than those previously reported for
health care workers [6]. Antibodies are expected to be
present in healthy subjects prior to vaccination with the
pandemic A/H1N1 vaccine [23,24] and are likely elicited by
natural exposure to cross-reactive influenza strains [25].
After vaccination, the seroconversion (48.3%) and ser-
oprotection (66.7%) rates increased, as did the antibody
GMTs (p < 0.0001). Although pandemic influenza vaccin-
ation induced a humoral response with a high fold in-
crease in the GMT (Table 2), our study most likely lacked
sufficient power to detect the seroprotection rate required
for vaccination success according to the international
criteria [19].
Furthermore, we performed a virus microneutralization
assay and observed a significant increase in the virus
neutralizing antibody titers after vaccination (p ≤ 0.0001,
Figure 1b). Although there are no standardized criteria to
apply for this method, our results showed that pandemic
influenza vaccination induced a limited humoral response
in this study group.
It has been reported that recent seasonal vaccination
can decrease antibody responses to the pandemic
A/H1N1 vaccine [6,26,27], but the mechanism of such a
phenomenon has not been explored. We investigated
whether the pre-existence of anti-HA1 antibodies played
a role in the decrease of the pandemic A/H1N1 vaccine
antibody responses in a subgroup of our study cohort that
included subjects who were seronegative for the specific
pandemic antibodies and were vaccinated with the sea-
sonal 2009 vaccine. We divided this group into individuals
who presented anti-HA1 antibodies prior to pandemic
A/H1N1 vaccination and individuals who did not. Our
results showed that after pandemic A/H1N1 vaccination,
the subjects without anti-HA1 antibodies prior to vaccin-
ation (n = 9) showed higher hemagglutination inhibition
antibody titers compared with subjects with anti-HA1
antibodies prior to vaccination (n = 13) (GMT 108.9 vs.
GMT 37.75, respectively, p = 0.14). However, this differ-
ence was not statistically significant. Thus, we cannot con-
clude that pre-existing antibodies to the seasonal vaccine
played a role in the induction of antibodies against the
pandemic A/H1N1 vaccine (Figure 1c).
T cell responses to pandemic influenza peptides
IFN-γ production
To evaluate vaccine-induced T cell reactivity, we assessed
IFN-γ production using PBMCs stimulated in vitro with





Age 37.1 ± 8.8
Immunization with 2008–2009 seasonal vaccine 8.3%
Immunization with 2009–2010 seasonal vaccine 75.0%
No prior seasonal vaccination 16.7%
Work-related direct contact with patients 21.1%
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specific peptides from pandemic A/H1N1 and the sea-
sonal virus using ELISPOT. The baseline frequency of
the IFN-γ-producing cells was moderate and compar-
able to that reported by others [28,29]. Prior to vaccin-
ation, a specific response to viral serotype peptides was
observed in a number of subjects and ranged from 22%
for the seasonal H3N2 peptide to 49% for the pandemic
A/H1N1 peptide 1 (Figure 2). Unexpectedly, after vac-
cination, IFN-γ production did not increase in response
to the specific pandemic A/H1N1 peptides or to pep-
tides from the seasonal strains.
There is controversy in the published data regarding
the specifics of IFN-γ production. For example, it has
been reported that only CD4+ and not CD8+ T cells pro-
duce IFN-γ in response to specific peptides after vaccin-
ation and that this cellular response is low but steady [30].
In contrast, another study reported that subjects without
confirmed exposure to the pandemic A/H1N1 virus could
generate higher numbers of IFN-γ spots from both CD4+
and CD8+ T cells to either pandemic A/H1N1 infection
with the whole vaccine virus or toward a peptide pool
[31,32]. In any case, no correlation was observed regarding
Figure 1 Increased humoral responses after pandemic influenza A/H1N1 vaccination. Specific antibodies against the pandemic influenza
virus A/H1N1 were measured via (a) hemagglutination inhibition and (b) microneutralization. The box plots show quartiles and medians. The
dotted lines indicate a cut-off value of 1:40, with p≤ 0.05 (pre-vaccination vs. post-vaccination), as determined using the Wilcoxon singed rank
test (n = 60). (c) The presence of IgG antibodies against hemagglutinin A/H1N1 (HA1) was assessed in sera obtained prior to H1N1 vaccination
using ELISA, with the dotted line indicating the cut-off value (n = 22). The antibody titers against the pandemic influenza virus A/H1N1 were
assessed post-vaccination in sera from individuals with (n = 13) or without (n = 9) anti-HA1 antibodies prior to vaccination using the
hemagglutination inhibition assay. The depicted box plots show the quartiles and medians. The dotted line indicates the protective cut-off value.
Table 2 Humoral response after pandemic H1N1 vaccination
Hemagglutination inhibition Microneutralization assays
Pre-vaccination Post-vaccination Pre-vaccination Post-vaccination
N 60 60 60 60
Seroprotection rate%a 6.7 66.7d NA NA
Seroconversion rate%b NA 48.3 NA NA
GMTc 6.8 64.9d 10.7 288.4d
GMT Fold-change NA 9.5 NA 26.9
aSeroprotection rate = percentage of subjects with hemagglutinin inhibition titers ≥ 1:40.
bSeroconversion rate = percentage of subjects with pre-vaccination hemagglutinin inhibition titers ≤ 1:10 and post-vaccination titers ≥ 1:40.
cGMT = geometric mean titer.
dp ≤ 0.05 vs pre-vaccination.
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antibody production in these studies; we also failed to de-
tect such a correlation in our study. In light of these find-
ings, our observation of the absence of a post-vaccination
response was unexpected and may be due to the selectiv-
ity of the immune response of antigen-specific cells that
can produce cell mediators, such as cytotoxic effectors, in
addition to IFN-γ [11].
CD4+ and CD8+ T cell proliferative responses
Prior to H1N1 vaccination, we observed proliferative re-
sponses in peripheral CD4+ and CD8+ T cells to pandemic
A/H1N1 peptides 1 and 2. Following A/H1N1 vaccination,
the proportion of proliferative CD8+ T cells significantly
increased (p < 0.05); however, the proliferation of CD4+ T





Figure 2 Frequency of IFNγ-producing cells in response to pandemic influenza peptides. Pre- and post-vaccination PBMCs were stimulated
with 10 μg/ml of pandemic H1N1 peptides 1 and 2, a common H1N1/H3N2 sequence, the seasonal H1N1 and H3N2 peptides (a-e), the whole
HA protein (f), a mixture of all the peptides (g) or PHA (h) for 48 h. Cells producing IFN-γ were enumerated using an ex-vivo ELISPOT assay. The
results are expressed as the number of SFCs per 106 PBMCs. Insets depict the percentage of subjects with a positive IFN-γ response pre- (dark)
and post-(light) vaccination.
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We do not believe that the lack of CD4+ T cell prolif-
eration was associated with limited class II peptide recog-
nition by these cells because the selected A/H1N1
peptides (1 and 2) are predicted to have a high affinity
for class I and class II recognition in the Mexican popu-
lation (Additional file 1: Table S1). In the case of prolif-
erative responses to H1N1 peptide 2, a decreasing trend
was observed in CD4+ T cell proliferation, although this
was not significant (p = 0.45) (Figure 3).
It is possible that the lack of a significant increase in
CD4+ T cell proliferation after H1N1 vaccination may
be due to a higher frequency of CD4+ T cells compared
with CD8+ T cells prior to vaccination, which in turn
could be induced by seasonal vaccination and/or natural
exposure to the influenza virus. It is also possible that
the absence of an adjuvant in the vaccine affected the
proliferation of CD4+ T cells. Similar to our results, a
previous report demonstrated that a non-adjuvanted H5N1
vaccine did not induce a robust expansion of CD4+ T
cells and failed to increase specific antibody titers [33].
Therefore, our results indicate that either the A/H1N1
vaccine had low CD4+ T cell immunogenicity or that the
A/H1N1 vaccine did not induce CD4+ T cell proliferation
in individuals who had previously received the seasonal
vaccine. In contrast to the CD4+ T cell responses, our
results indicated that the A/H1N1 vaccine induced sig-
nificant CD8+ T cell proliferation in individuals who had
previously received the seasonal vaccine. Additionally,
we did not find a correlation between CD4+ or CD8+ T
cell proliferation and the antibody production induced
by vaccination.
In summary, our results indicate that pandemic vac-
cination induces CD8+ T cell clonal expansion, as dem-
onstrated by the increase in the proliferative response to
A/H1N1 peptides. This result is consistent with previous
reports demonstrating that CD8+ T cells proliferate after
influenza vaccination [28,31]. We hypothesize that the
extent of CD8+ T cell clonal expansion that we observed
following H1N1 pandemic vaccination may be linked to
the cytolytic effector functions of cells rather than the
Figure 3 Proliferative T cell responses to pandemic H1N1 and seasonal peptides. CFSE-labeled PBMCs (1 × 106) were stimulated with
10 μg/ml of pandemic A/H1N1 peptides 1 and 2 for 7 days. The cells were stained with anti-human CD3PE-Texas Red, CD8PE-Cy7 and CD4APC-Cy7
and then analyzed using flow cytometry. The plots show the percentages of proliferating CD4+ or CD8+ T cells prior to and after A/H1N1 vaccination (n = 32).
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generation of antigen-specific long-lived plasma cells and
the direct effector functions mediated by IFN-γ [34].
Furthermore, to analyze the cross-reactivity of seasonal
serotypes, we evaluated the percentages of CD8+ T cells
proliferating in response to specific peptides correspond-
ing to seasonal H1N1 and H3N2 serotypes. We found
that approximately 5% of the CD8+ T cells proliferated
in response to pandemic and seasonal peptides prior to
vaccination (Figure 4a). This finding may be associated
with previous seasonal vaccination because most of the
individuals had received a seasonal vaccination approxi-
mately 2 months prior to the pandemic vaccination. How-
ever, this finding could also be associated with the presence
of cross-reactive virus-specific CD8+ memory T cells, as re-
ported by others [35]. Our results also showed a significant
increase in CD8+ T cell proliferation in response to pan-
demic and seasonal influenza-specific peptides after pan-
demic A/H1N1 vaccination (p < 0.05) (Figures 3 and 4a).
No significant differences were detected in the percentage
of proliferating CD8+ T cells between the pandemic and
seasonal type A viruses. Among individuals with positive
proliferative responses, 29%, 13% and 37% had pre-existing
CD8+ T cells specific to the pandemic A/H1N1, seasonal
H1N1 and seasonal H3N2 peptides, respectively. One
month after pandemic vaccination, the percentage of posi-
tive subjects increased to 70.8% (p < 0.05) for the pan-
demic A/H1N1 serotype and to 43% (p < 0.05) and 47%
(p > 0.05) for the seasonal H1N1 and H3N2 serotypes,
respectively (Figure 4b). These data indicate that after
pandemic A/H1N1 vaccination, the number of individ-
uals with antigen-specific proliferating CD8+ T cells in-
creased; this assessment may serve as a complementary
parameter for evaluating the immunological success of
influenza vaccines.
Conclusions
Our results showed that cellular immune responses that
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Figure 4 Pandemic H1N1 vaccination induced CD8+ T cell proliferation to pandemic H1N1, seasonal H1N1 and H3N2 peptides. CFSE-labeled
PBMCs (1 × 106) were stimulated with 10 μg/ml of the pandemic H1N1 and seasonal H1N1 and H3N2 peptides for 7 days. The cells were harvested
and stained with anti-human CD3PE-Texas Red and CD8PE-Cy7 and analyzed using flow cytometry. (a) Percentages of the CD8+ T cell proliferation
pre-vaccination and post-vaccination in response to seasonal H1N1 and H3N2 peptides. The means and standard errors are shown, with p≤ 0.05
pre-vaccination vs. post-vaccination, according to the Wilcoxon matched-pairs signed rank test. (b) Percentages of positive subjects responding to
the pandemic H1N1 peptides 1 and 2 (p < 0.05) and the seasonal influenza A H1N1 (p < 0.05) and H3N2 serotypes post-vaccination (p > 0.05).
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be present in populations exposed to the circulating
seasonal influenza virus prior to pandemic or seasonal
vaccination. The pandemic vaccine induced a significant
increase in CD8+ T cell proliferation.
Additional file
Additional file 1: Table S1. Peptide sequences and predicted
recognition by class I and class II HLA alleles frequently found in Mexicans.
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